Posted July 2, 2012
GSK
By Staff, wire reports
Trial results boost potential GSK blockbuster respiratory drug
1 comment | Post Yours
Print this storyE-mail story
Share
GSK
Research Triangle Park, N.C. —
The drug to treat patients with chronic obstructive pulmonary disease under development could mean $3.5 billion or more a year in sales for Glaxo and replace its best-selling Advair, analysts say....Copyright 2013 WRAL Tech Wire. All rights reserved.
Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
| page 1 |
They're probably already trying to figure out what maladies they can market it for that are not approved by the FDA...
| page 1 |
Please Log In to add a comment.
